A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge

Louise Westberg Strejby Christensen*, Esben Iversen, Aino Leegaard Andersen, Anne Byriel Walls, Line Jee Hartmann Rasmussen, Ove Andersen, Thomas Kallemose, Morten Baltzer Houlind

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

3 Downloads (Pure)

Abstract

Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic chronic inflammation. Elevated suPAR levels are associated with adverse clinical outcomes, but a small subset of patients with low suPAR also experience poor outcomes. Therefore, we aimed to characterize patients presenting to the emergency department with low suPAR (<3 ng/mL) who died within 90 days after discharge in a registry-based study. Compared to patients with low suPAR who survived (n = 15 122), those who died within 90 days (n = 87) had higher age (75.4 years), higher medication use (7.0; 71.3% with polypharmacy) and more blood tests outside reference intervals (5.0) (including C-reactive protein, neutrophils and albumin), and the most common diagnoses were chronic pulmonary disease (27.6%), cerebrovascular disease (18.4%) and dementia (11.5%). Patients with low suPAR were more morbid than what was reflected by suPAR alone. Future studies must determine which factors that contribute the most to potential algorithms when stratifying patients based on their risk of adverse clinical outcomes. These data indicate that inclusion of medication data could be relevant.

Original languageEnglish
JournalBasic and Clinical Pharmacology and Toxicology
Volume135
Issue number3
Pages (from-to)364-371
ISSN1742-7835
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Keywords

  • adverse clinical outcomes
  • medication review
  • mortality
  • polypharmacy
  • risk stratification
  • suPAR

Cite this